Formosa Pharmaceuticals, Inc. (TPE:6838)

Market Cap	3.73B -21.2%
Revenue (ttm)	52.59M +237.4%
Net Income	-190.05M
EPS	-1.26
Shares Out	150.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,065
Open	24.30
Previous Close	24.70
Day's Range	23.75 - 24.40
52-Week Range	22.35 - 33.30
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and color...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6838

Financial Performance

In 2025, Formosa Pharmaceuticals's revenue was 9.50 million, a decrease of -93.38% compared to the previous year's 143.36 million. Losses were -83.57 million, -58.43% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error